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The sodium channel blocker mexiletine is considered the ﬁrst-line drug in myotonic syndromes, a group
of muscle disorders characterized by membrane over-excitability. We previously showed that the b-
adrenoceptor modulators, clenbuterol and propranolol, block voltage-gated sodium channels in
a manner reminiscent to mexiletine, whereas salbutamol and nadolol do not. We now developed
a pharmacological rat model of myotonia congenita to perform in vivo preclinical test of antimyotonic
drugs. Myotonia was induced by i.p. injection of 30 mg/kg of anthracene-9-carboxylic acid (9-AC),
a muscle chloride channel blocker, and evaluated by measuring the time of righting reﬂex (TRR). The TRR
was prolonged from <0.5 s in control conditions to a maximum of w4 s, thirty minutes after 9-AC
injection, then gradually recovered in a few hours. Oral administration of mexiletine twenty minutes
after 9-AC injection signiﬁcantly hampered the TRR prolongation, with an half-maximum efﬁcient dose
(ED50) of 12 mg/kg. Both propranolol and clenbuterol produced a dose-dependent antimyotonic effect
similar to mexiletine, with ED50 values close to 20 mg/kg. Antimyotonic effects of 40 mg/kg mexiletine
and propranolol lasted for 2 h. We also demonstrated, using patch-clamp methods, that both propranolol
enantiomers exerted a similar block of skeletal muscle hNav1.4 channels expressed in HEK293 cells. The
two enantiomers (15 mg/kg) also showed a similar antimyotonic activity in vivo in the myotonic rat.
Among the drugs tested, the R(þ)-enantiomer of propranolol may merit further investigation in humans,
because it exerts antimyotonic effect in the rat model, while lacking of signiﬁcant activity on the b-
adrenergic pathway. This study provides a new and useful in vivo preclinical model of myotonia con-
genita in order to individuate the most promising antimyotonic drugs to be tested in humans.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The non-dystrophic myotonic syndromes are a set of disorders
targeting skeletal muscles, characterized by muscle stiffness
following contraction or percussion. The pathology is caused by
mutations in genes encoding voltage-dependent chloride channels
(CLCN1 gene, ClC-1 protein) or sodium channels (SCN4A gene,
Nav1.4 protein), which are expressed exclusively in skeletal
muscles (Matthews et al., 2010). Loss-of-function mutations of ClC-
1 channels or gain-of-function mutations of Nav1.4 channels
pathologically increase sarcolemma excitability with occurrence of
abnormal action potentials runs and consequent difﬁculties in
muscle relaxation, determining the muscle stiffness characteristic
of myotonic muscle.nthracene-9-carboxylic acid.
7.
esaphy).
-NC-ND license.Today the pharmacotherapy of myotonic syndromes, resulting
either from chloride or sodium channel mutations, is based
essentially on the use of sodium channel blockers, which reduce
sarcolemma excitability by inhibiting action potentials (Conte
Camerino et al., 2007). The preferred drug is mexiletine, a class Ib
antiarrhythmic, used at rather high doses (Lehmann-Horn et al.,
2008; Matthews et al., 2010). Preferential binding to inactivated
channels and use-dependent block are thought to constitute the
basis of the selective action of mexiletine on pathologic hyperactive
tissues. However, not all the patients take beneﬁts frommexiletine,
which can induce side effects limiting patient compliance,
including epigastric discomfort, nausea, tremor, anxiety and
headaches. Patients with cardiac diseases may avoid mexiletine.
Moreover lack of mexiletine efﬁcacy has been observed in
a number of patients, most probably in relation to pharmacogenetic
mechanisms (Desaphy et al., 2004). In addition, mexiletine has
beenwithdrawn from the market in several countries. Thus there is
a critical need for the individuation of new efﬁcient and safe anti-
myotonic drugs.
J.-F. Desaphy et al. / Neuropharmacology 65 (2013) 21e2722In a previous study, we showed that drugs known as modulators
of b-adrenergic receptors are able to block sodium channels in
a manner reminiscent to local anesthetic drugs (Desaphy et al.,
2003). The b2-agonist clenbuterol and the b-antagonist propran-
olol showed efﬁcacies comparable to mexiletine in producing use-
dependent inhibition of sodium currents in rat skeletal muscle
ﬁbers, as well as in tsA201 cells transiently expressing the human
muscle sodium channel isoform, hNav1.4. In contrast, the b-agonist
salbutamol and the b-antagonist nadolol had no effect on sodium
currents at 1 mM concentration. Examination of chemical struc-
tures and physicochemical properties of these drugs revealed the
presence of the two pharmacophores important for sodium
channel blocking activity, the tertiary amine and the aromatic ring,
which confer respectively a high pKa and a high lipophilicity.
However, the two inactive compounds are characterized by the
presence of two hydroxyl groups on the aromatic moiety, which
appeared to be determinant for impeding sodium channel blockade
(Desaphy et al., 2012). Accordingly, clenbuterol was shown to
inhibit action potential ﬁring in skeletal muscle ﬁbers, whereas
nadolol did not (Desaphy et al., 2003).
In the present study, we evaluated in vivo the antimyotonic
activity of these b-adrenergic drugs compared to that of mexiletine.
For this, we have developed an animal model of myotonia allowing
a quantitative preclinical study. We have chosen to use a pharma-
cological model rather than the available genetic models, because it
offers a large availability of animals, it allows to measure myotonia
in a reproducible way through a non-invasive method, and it is
cheaper. In this model, myotonia is induced in adult rats by a single
intraperitoneal injection of anthracene-9-carboxylic acid (9-AC). By
blocking muscle ClC-1 channels, 9-AC is able to induce a myotonic
state similar to chloride channel myotonia (Bryant and Morales-
Aguilera, 1971; Furman and Barchi, 1978; Estevez et al., 2003).
The myotonic state was evaluated by calculating the time of
righting reﬂex (TRR), that is the time taken by the rat to turn back
on his four limbs after being posted in supine position. An anti-
myotonic drug is expected to shorten the TRR induced by 9-AC.
The results demonstrate that both clenbuterol and propranolol
show a time-dependent antimyotonic effect in the dose range of 5e
40 mg/kg, quite similar to that of mexiletine. In contrast, either the
b2-agonist salbutamol or the b-antagonist nadolol, both unable to
block sodium channels, did not show any signiﬁcant antimyotonic
effect. We also demonstrated that both propranolol enantiomers
produced undistinguishable hNav1.4 sodium channel block in vitro
and antimyotonic activity in vivo. We thus propose the R(þ)-
enantiomer of propranolol, which is inactive on b-adrenor-
eceptors, as a possible alternative to mexiletine in the treatment of
myotonic syndromes.Fig. 1. Experimental design. (A) A daily experiment forecasted the use of 4 animals
extracted from a reserve pool of 20 rats. The four animals received a single i.p. injection
of 9-AC, 30 mg/kg, and 20 min after, a dose of either mexiletine or exploratory drugs,
or the drug vehicle alone. (B) Myotonia state was assayed by measuring the time of
righting reﬂex (TRR), that is the time taken by the rat to turn back on his four limbs,
after being posted in supine position. The TRR was measured 10 min before, and 10, 30,
60, 120, and 180 min after 9-AC injection. At each time point, the TRR value was
calculated as the mean of seven determinations. (C) In control condition (before 9-AC
injection), the TRR is less than 0.5 s. After 9-AC and drug vehicle administration, the
TRR increased up to >3 s. An antimyotonic drug is expected to reduce the TRR to less
than 3 s. At the end of the experiment, the rats were allowed to rest for at least 48 h
before being reintegrated in the reserve pool.2. Materials and methods
2.1. Sodium current measurement in HEK293 cells
Whole-cell sodium currents (INa) were recorded with patch-clamp technique in
HEK293 cells permanently transfected with the human skeletal muscle isoform of
voltage-gated sodium channel, hNav1.4 (Desaphy et al., 2012). Sodium current
recordings were performed at room temperature (20e22 C) using an Axopatch 1D
ampliﬁer (Axon Instruments, Union City, CA, USA). Voltage clamp protocols and data
acquisition were performed with pCLAMP 9.2 software (Axon Instruments) through
a 12-bit A-D/D-A interface (Digidata 1340, Axon Instruments). Pipettes made with
Corning 7052 glass (Garner Glass, Claremont, CA, USA) had resistance that ranged
from 1 to 3 MW. Currents were low-pass ﬁltered at 2 kHz (3 dB) by the four-pole
Bessel ﬁlter of the ampliﬁer and digitized at 10e20 kHz. After the patch membrane
had been ruptured, a 25-ms-long test pulse to 30 mV from a holding potential
of 120 mV was applied to the cell at a low frequency until stabilization of sodium
current amplitude and kinetics was achieved (typically 5 min). Only those data
obtained from cells exhibiting series resistance errors <5 mV were considered for
analysis. Little (<5%) or no rundown was observed within the experiments.2.2. Animal care and in vivo experiments
The experiments have been performed in accordancewith the Italian Guidelines
for the use of laboratory animals, which conforms with the European Union
Directive for the protection of experimental animals (2011/63/EU), and received
approval from the Animal Experimentation Ethic Committee of the University of
Bari-Aldo Moro (CESA). All efforts were made to minimize animal suffering and to
reduce the number of animals used.
Adult WISTAR rats (350e500 g) were purchased from Charles River e Italy. A
total of 20 rats were housed individually and given food and water ad libitum. In
a typical daily experiment, three/four rats were randomly extracted from this pool to
receive an intraperitoneal injection of 30mg/kg anthracene-9-carboxylic acid (9-AC)
(Fig. 1A). Ten minutes after 9-AC injection, the animals received drug or vehicle per
os using an esophageal cannula (Fig. 1B). Myotonia state was assayed by measuring
the time of righting reﬂex, that is the time taken by the rat to turn back on his four
limbs after having been positioned in supine position. Ambient temperature was
maintained to 20e22 C. The TRR was determined 10 min before and 10, 30, 60, 120,
and 180min after 9-AC administration. At each time point, the TRRwas calculated as
the average of 7 determinations to obtain a S.E.M. minor than 10% of the mean. A 1-
min interval was respected between two measures to avoid any warm-up
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J.-F. Desaphy et al. / Neuropharmacology 65 (2013) 21e27 23phenomenon. Typically, a control rat takes less than 0.5 s to turn back on his limbs,
whereas, 30 min after 9-AC injection, a myotonic rat shows a TRR greater than 3 s
(Fig. 1C). A drug with antimyotonic activity is expected to reduce the TRR with
respect to the TRRmeasured in the rat receiving drug vehicle only. Effect of 9-ACwas
maximal 30 min after injection and reversed spontaneously within 15 h. This
protocol was used to evaluate the doseeresponse relationships for mexiletine,
propranolol, and clenbuterol. A second protocol was used to evaluate the duration of
antimyotonic effect of a single drug administration; In this case, the exploratory
drug was administrated 120, 90, 60, or 30 min before 9-AC, and the TRR (mean of 7
determinations) was measured 30 min after 9-AC. This protocol was performed
contemporaneously in 3 rats, one of which receiving 40 mg/kg mexiletine, an other
receiving 40 mg/kg propranolol, and the third one receiving only vehicle.
At the end of each experimental day, the tested rats were allowed a resting
period of at least 48 h before to reintegrate the reserve pool. By the end of the study,
animals were reinserted in the animal quarter.
For each drug dose, the protocols were repeated on three-to-six days in different
rats, and the experimental points are given as the mean  S.E.M. Statistical analysis
was performed using one-way analysis of variance (ANOVA) followed by ad-hoc
Bonferroni’s t test. A P value minor to 0.05 was considered statistically signiﬁcant.
2.3. Drugs and solutions
Patch clamp pipette solution contained in mM: 120 CsF, 10 CsCl, 10 NaCl, 5 EGTA
and 5 HEPES, and the pH was set to 7.2 with CsOH. Bath solution for patch clamp
recordings contained (in mM): 150 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 5 HEPES and 5
glucose. The pH was set to 7.4 with NaOH. All the compounds were purchased from
SigmaeAldrich (Milan, Italy).
Mexiletine hydrochloride, 9-anthracenecarboxylic acid (9-AC), salbutamol,
clenbuterol hydrochloride, nadolol, DL-propranolol hydrochloride and its R(þ) and
S() enantiomers, hydrochloride salts, were purchased from Sigma-Aldrich (Milan,
Italy). For patch-clamp experiments, racemic propranolol and its single enantiomers
were dissolved directly in external patch solution at the desired ﬁnal concentration.
The patched cell was continuously exposed to a stream of control or drug-
supplemented bath solution ﬂowing out from a plastic capillary. For in vivo exper-
iments, a solution of 2.4 g/l 9-ACwas prepared each day in distilled water containing
0.3% bicarbonate; The volume of i.p. injection was adjusted to get 30 mg/kg body
weight. The choice of 9-AC dose was based on preliminary experiments, indicating
30 mg/kg as the lower dose producing a reproducible myotonia, assayed by TRR, in
100% of treated rats (not shown). Exploratory drugs were diluted at the desired
concentration directly in physiological 0.9% NaCl saline for oral administration of
a volume close to 1 ml. The choice of drug doses was based on the usual clinical dose
of mexiletine in humans, that is 3e8 mg/kg a day. Thus we ﬁrst tested 5 mg/kg
mexiletine and other compounds, and then increased the dose up to 40 mg/kg to
draw a doseeresponse curve.T im e  ( m in )
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Fig. 2. Time course of myotonic effect of 9-AC. (A) The myotonic effect induced by
30 mg/kg 9-AC was evaluated by measuring the TRR, as shown in Fig. 1. Time zero
corresponds to 9-AC injection. Each circle represents the TRR measured in each rat
(mean from sevendeterminations), while bars show themean S.E.M. of TRR calculated
from the 20 tested rats. Statistical analysis was performed with one-way ANOVA fol-
lowed by ad-hoc Bonferonni’s t-test (ANOVA parameters: F¼ 96.35; k-1¼5; N-k¼ 114;
P< 0.0001). All TRRmean values resulted signiﬁcantly different from the others (at least
P< 0.04), except TRR (60) and TRR (10) that were not signiﬁcantly different. (B) The TRR
valuemeasured 30min after 9-AC injectionwas linearly correlated to the TRRmeasured
10 min after 9-AC (r2 ¼ 0.77). (C) The TRR values determined at each time point were
normalized with respect to the TRR value measured 10 min after 9-AC injection.3. Results
3.1. Reproducible myotonia induced by 9-AC
Myotonia was induced in rats by intraperitoneal injection of
30 mg/kg 9-AC. Soon after 9-AC injection, the rats show evident
stiffness and difﬁculties to move. Nevertheless, the animals
remained fully conscious and alert. Breathing appeared normal.
When hearing an unexpected noise, the animals reacted by a jump
on site but had great difﬁculties to move away due to muscle
stiffness. Myotoniawas evaluated bymeasuring the time of righting
reﬂex.
Fig. 2A shows the time course of TRR measured in a number of
rats having received i.p. 9-AC and oral drug vehicle, according to the
protocol described in Fig. 1B. Ten minutes before 9-AC injection the
TRR was less than 0.5 s. The TRR was dramatically prolonged to
w2 s 10 min after 9-AC, and increased further tow4 s 30 min after
9-AC. Then the TRR decreased gradually over time, being close to 1 s
3 h after 9-AC. Statistical comparison of TRRmean values measured
at each time point was performed using one-way ANOVA followed
by ad-hoc Bonferroni’s t-test (ANOVA parameters: F ¼ 96.35; k-
1 ¼ 5; N-k ¼ 114; P < 0.0001). All TRR mean values resulted
signiﬁcantly different from the others (at least P< 0.04), except TRR
(60) and TRR (10) that show no signiﬁcant difference. The TRR was
fully recovered within 15 h after 9-AC injection (not shown).
Myotonia developed in all the tested rats with the same kinetics,
and the individual responses of rats showed reasonable variability.
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Fig. 3. Antimyotonic effects of exploratory drugs. The time course of normalized TRR
values was determined in 9-AC treated rats receiving either 40 mg/kg (A) or 5 mg/kg
(B) of exploratory drugs or relative vehicle. Each curve is the mean  S.E.M. calculated
from 3-to-9 rats. Statistical comparison was performed between all the tested drugs
at each time point using one-way ANOVA followed by ad-hoc Bonferroni’s t-test.
At 40 mg/kg, mexiletine, propranolol, and clenbuterol signiﬁcantly reduced the TRR at
30-, 60-, and 120-min time points compared to vehicle (at least P < 0.05, see Section
3.2 for details). At 5 mg/kg, mexiletine, propranolol, and clenbuterol signiﬁcantly
J.-F. Desaphy et al. / Neuropharmacology 65 (2013) 21e2724Quite similar variability in peak myotonia was also observed
between two 9-AC injection performed in a single rat on different
days (not shown). Importantly, we observed that the peak TRR
measured at time 30 min was linearly correlated to the TRR
measured at 10 min (Fig. 2B), suggesting that the TRR measured at
the 10 min-time point was a predictive indicator of the full
response in each animal. Thus we normalized the TRR (t) as
a function of TRR (10min) as shown in Fig. 2C, as a useful maneuver
to compare myotonia between rats receiving the various drugs or
vehicle.
3.2. Antimyotonic effects of mexiletine and beta-adrenergic drugs
Mexiletine is today considered a ﬁrst-line drug in myotonic
patients (Lehmann-Horn et al., 2008), and exerted antimyotonic
effect in vivo in the adr (arrested development of righting response)
myotonic mouse (De Luca et al., 2004). In 9-AC treated rats, oral
mexiletine, 40 mg/kg, produced a drastic reduction of TRR with
respect to vehicle, as soon as 10 min after administration (Fig. 3A).
Statistical comparison of all the tested drugs and vehicle was per-
formed at each time point using one-way ANOVA followed by ad-
hoc Bonferroni’s t-test. Mexiletine reduced the TRR (30 min) by
77.8 2.2% (n¼ 6, P< 0.0001). The antimyotonic effect of 40 mg/kg
mexiletine was still signiﬁcant after 40 (P < 0.0001) and 100
(P < 0.005) minutes, but was minimal after 160 min. Actually, the
absolute TRR value remained quite constant over time in presence
of mexiletine, suggesting that 40 mg/kg may be close to the
maximal mexiletine efﬁcient dose. The effects of mexiletine were
dose-dependent. Effects of 5 mg/kg are shown in Fig. 3B. The
reduction of TRR (30) by mexiletine with respect to vehicle was
33.5  9.3% (n ¼ 4, P < 0.005), whereas antimyotonic effect dis-
appeared as soon as 40 min after mexiletine administration. The
antimyotonic effect of 15 mg/kg mexiletine was also measured in 3
rats and was statistically signiﬁcant 10 and 40 min after drug
administration (not shown). The doseeresponse relationship was
constructed for antimyotonic effect of mexiletine on TRR (30)
(Fig. 3C). The ﬁt of this relationship (see ﬁt equation in Fig. 3 legend)
indicated an half-maximal efﬁcient dose (ED50) of 12.2  2.3 mg/kg
and a slope factor (nH) of 0.9  0.2 (means  S.E. of the ﬁt).
The antimyotonic activity of b2-adrenoceptor agonists, salbu-
tamol and clenbuterol, and b-antagonists, nadolol and propranolol,
were tested in parallel to mexiletine (Fig. 3). At 40 mg/kg, both
salbutamol (n ¼ 3) and nadolol (n ¼ 3) did not show any signiﬁcant
antimyotonic effect. In contrast clenbuterol and propranolol
induced antimyotonic effects quite similar to mexiletine, although
with a reduced efﬁciency. The TRR (30) was reduced by 64.8  2.9%
with propranolol (n ¼ 4, P < 0.0001) and 62.8  2.9% with clen-
buterol (n ¼ 4, P < 0.0001), and signiﬁcant antimyotonic effect was
also observed after 40 (P< 0.0001 for propranolol and P< 0.001 for
clenbuterol) and 100 (P < 0.01 for propranolol and P < 0.05 for
clenbuterol) minutes. At 5 mg/kg, antimyotonic activities on TRR
(30) of propranolol and clenbuterol were lower than that of mex-
iletine but still statistically signiﬁcant (P< 0.05 for both drugs). The
ED50 values were 22.6  2.4 mg/kg (nH ¼ 0.8  0.1) for clenbuterol
and 19.4  3.2 mg/kg (nH ¼ 1.0  0.2) for propranolol (Fig. 3C).
To compare the duration of antimyotonic effect of mexiletine
and propranolol, we modiﬁed the protocol as shown in Fig. 4A. Thereduced the TRR only at the 30-min time point. (C) The doseeresponse curve were
constructed for mexiletine, propranolol, and clenbuterol by reporting the value of
normalized TRR (expressed as percentage of normalized TRR measured in rat receiving
drug vehicle alone) measured 10 min after drug administration (i.e. 30 min after 9-AC
injection). The doseeresponse curve were ﬁtted with equation TRR ¼ 100/[1 þ exp
([Drug]/ED50)nH], where [Drug] is the drug dose, ED50 is the half-maximum efﬁcient
dose, and nH is the slope factor. Values of ﬁt parameters are given in Section 3.2.
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J.-F. Desaphy et al. / Neuropharmacology 65 (2013) 21e27 25TRR was measured only once, 30 min after 9-AC injection, but
either drug (40 mg/kg) or vehicle were orally administrated to
different groups of animals at various time points from 150 to
10 min before TRR measurement. The TRR values measured in
drug-treated rats were normalized with respect to the TRR
measured in rat receiving the vehicle alone and reported as
a function of time (Fig. 4B). The time courses for propranolol and
mexiletine were quite similar. Effect was maximum 10 min after
drug administration, remained quite constant for 2 h, and dropped
drastically after 150 min.
3.3. Sodium channel blockade and antimyotonic effects of
propranolol enantiomers
Although propranolol is clinically used as a racemic mixture,
a number of evidences indicate that only the S()-enantiomer
displays b-adrenoceptor antagonism and exerts hemodynamic
effects in humans (Stoschitsky et al., 1989; Mehvar and Brocks,
2001). Sodium channel blockade by propranolol has been demon-
strated by us and others (Fischer, 2002; Desaphy et al., 2003; Wang
et al., 2010; Bankston and Kass, 2010), and both enantiomers
appeared to exert a similar effect at least on cardiac sodium
channels (Fischer, 2002; Wang et al., 2010). Here we compared the
effects of racemic propranolol and single enantiomers (100 mmol/l)
on the skeletal muscle hNav1.4 sodium channel isoform expressed
in HEK293 cells. Representative sodium current traces in Fig. 5A
illustrate the huge use-dependent block of hNav1.4 channels by R-
propranolol. The drug blocked sodium currents by 64.7  13.5% at
0.1 Hz stimulation frequency and 92.9  2.9% at 10 Hz (n ¼ 3).Similar results were obtained with the 3 compounds, showing the
lack of stereoselectivity for propranolol in blocking sodium chan-
nels (Fig. 5B). The two single propranolol enantiomers were also
tested in vivo for antimyotonic activity in the 9-AC treated rat. We
tested the dose of 15 mg/kg, which is close to the ED50 of racemic
propranolol, in order to detect any potential difference between
drugs efﬁcacies. Both enantiomers reduced the TRR (30) to the
same extent of the racemic mixture.
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In this study, we developed a new pharmacological in vivo rat
model of myotonia congenita to evaluate the antimyotonic activity
of mexiletine and b-adrenergic drugs.
Genetic animal models of myotonia include adr or mto (a
myotonic mutant mouse arisen spontaneously at the Jackson
laboratories; Heller et al., 1982) mice, dogs, and goats (Matthews
et al., 2010). Although these models have proven very useful for
the understanding of the physiopathology of myotonia, their use for
preclinical screening of drugs shows obvious limitations. Dogs and
goats are difﬁcult and expensive to breed in the laboratory and their
use raises ethical issues. In the adr or mto mice, myotonia is
inherited in a recessive mode and is very severe. Myotonia that
develops very early after birth hampers normal animal growth,
induces skeletal malformation, and signiﬁcantly reduces life
expectancy. The myotonia severity can vary substantially among
individuals and worsens with age. The myotonic mice are very
delicate to manipulate and support repetitive exercise with great
difﬁculty. Nonetheless, myotonic mice were successfully used, with
many precautions, by us and others to test some antimyotonic
drugs administrated by i.p. injection (Aichele et al., 1985; De Luca
et al., 2004). Because of their small size and extreme fragility, the
use of an esophageal cannula for oral administration of drugs is
quite difﬁcult in myotonic mice. One of the advantages of the rat
model used in this study is indeed the possibility to use oral
administration of drugs, which is the common way used by
patients. Other advantages include the very limited stress held to
rats, the easy standardization of protocols, the reduced number of
animals needed to obtain experimental points, and the reduced
costs of experimentation. The aromatic monocarboxylic acids have
been shown to produce myotonia in mammalian skeletal muscle by
blocking muscle chloride channels, 9-AC being the most potent
(Bryant and Morales-Aguilera, 1971; Palade and Barchi, 1977).
Single i.p. doses of 9-AC, 5 or 8 mg/kg, in rats induces electro-
myographic myotonia as early as a few minutes after administra-
tion, including action and percussion myotonia as well as a warm-
up phenomenon (Mrozek et al., 1974; Conte Camerino et al., 1989).
A doseeresponse curve was only performed in a single anes-
thetized goat, suggesting an ED50 close to 4 mg/kg 9-AC for
percussion myotonia (Bryant and Morales-Aguilera, 1971). In
preliminary experiments, we tested 5, 10, and 30 mg/kg 9-AC using
the TRR test in a larger number of rats (not shown). Although
myotoniawas observed at all the three doses, a consistent myotonic
response (maximal TRR 30 min after 9-AC administration observed
in 100% of the tested animals) was observed only at the higher dose,
that is less than 8 times the estimated ED50 in goats. Thus 30 mg/kg
was the lowest dose inducing reproducible behavioral myotonia
allowing an easy quantiﬁcation by means of the non-invasive TRR
test. The effects of 9-AC were fully reversible within 15 h, and no
side effects were observed even after repeated administration.
We can note here that a myotonia-like state can be also ob-
tained in vivo with chemicals affecting sodium channels, including
veratrinic agents. Nevertheless, such a model may not be adapted
to the current study because the veratrinic agents acts on both
nerve and muscle sodium channels and may generate drug inter-
action with the exploratory compounds (Ulbricht, 1998). Impor-
tantly, no toxic effect of 9-AC has been observed on action
potentials recorded in isolated rat diaphragm muscle ﬁbers at
concentrations up to 25 times the Ki for reduction of sarcolemma
chloride conductance, indicating lack of direct effects of the drug
on sodium channels as well as on resting membrane potential
(Furman and Barchi, 1978). From these results, we can conclude
that an effect of 9-AC on nerve excitability is very unlikely in our
experimental conditions.Up today, the study of potential countermeasures against
myotonia induced by 9-AC has been performed only in vitro
(Dengler and Rudel, 1979; van Lunteren et al., 2011; Su et al., 2012).
Therefore one important novelty of the model described here is
that drugs are tested in vivo in conscious animals. The model as
shown here may present some limitations, especially regarding
long term studies aimed at testing repeated administration of drugs
or sustained-release drug formulations, which would merit to be
addressed in future experiments. Nonetheless, we were able to
perform a quantitative analysis of dose-dependent acute effects of
antimyotonic drugs in vivo.
Mexiletine, the preferred drug in myotonic humans, produced
a dose-dependent antimyotonic effect in the 9-AC treated rat, as
expected. The ED50 value for oral mexiletine in the myotonic rat
(12 mg/kg) is comparable to that measured in the adr mouse for i.p.
mexiletine, in which 5 mg/kg produced a w50% reduction of TRR
(De Luca et al., 2004). In humans, when needed, treatment for
myotonia relief may require up to 800 mg a day mexiletine (Dr.
Mauro LoMonaco, Catholic University, Rome, personal communi-
cation), which closely corresponds to the mexiletine ED50 found in
the animal models. The dose of 40 mg/kg appeared likely close to
the maximal efﬁcient mexiletine dose in the rat; At this dose,
mexiletine effects developed very rapidly and lasted for 2 h. Higher
doses were not tested because of risks of undesirable life-
threatening side effects.
A number of evidences suggest that mexiletine effects are
related to sodium channel blockade in vivo, thereby reducing over-
excitability in myotonic ﬁbers independently of the genetic origin.
Our results conﬁrm such hypothesis since clenbuterol, propranolol,
and single propranolol enantiomers, which all display sodium
channel blockade and action potential ﬁring inhibition in vitro,
exerted antimyotonic effects in vivo, whereas nadolol and salbu-
tamol did not. Clearly, the antimyotonic effects of these compounds
were not related to modulation of the b-adrenergic pathway.
Despite clenbuterol and propranolol showed greater efﬁciency in
blocking hNav1.4 sodium channels in HEK cells (Desaphy et al.,
2003), their antimyotonic efﬁcacy was slightly lower than that of
mexiletine. Such an apparent discrepancy may be due to differ-
ences in pharmacokinetics or to the inappropriateness of voltage
clamp protocols used in cell lines. Indeed sodium currents were
recorded in HEK cells using a holding potential of 120 mV, which
is more negative than muscle cell membrane potential, and
a stimulation frequency of 10 Hz, which is likely less than the
frequency of action potential runs in the myotonic muscle ﬁber.
Future studies will be performed to assess sodium channel inhibi-
tion in HEK cells using more physio/pathological conditions.
In our hands, the b2-agonist clenbuterol displayedmore variable
antimyotonic efﬁciency at lower doses and undesirable side effects
at the highest dose, including generalized weakness and breathing
difﬁculties (not shown). Propranolol was safe of side effects and
produced constant antimyotonic activity lasting two hours, such as
mexiletine. The propranolol ED50was 19mg/kg compared to 12mg/
kg for mexiletine. In the clinical setting, propranolol is used essen-
tially for cardiovascular diseases at doses ranging between 80 and
320 mg a day, corresponding to a maximal dose ofw5 mg/kg. It is
possible that antimyotonic effect in humans may thus require
dosages in the higher range. It is noteworthy that sporadic cases of
myotonia aggravation have been reported in humanswith the use of
b2-agonists as well as with b-blocking adrenergic agents (Blessing
and Walsh, 1977; Ricker et al., 1978), and use of such drugs is
generally not recommended (Chrestian et al., 2006; Duno and
Colding-Jorgensen, 2011). Regarding propranolol, the inhibition of
b-adrenoceptor would favor musclemembrane depolarization, that
is thought to facilitate myotonia. Although we never observed
myotonia exacerbation by propranolol in the rat model, a valuable
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patientswould be to use the single R(þ)-enantiomer of propranolol,
instead of the racemic mixture. Indeed the R(þ)-enantiomer is
w100 times less active on b-adrenoceptor pathway than the S()-
enantiomer (Barrett and Cullum, 1968), but both stereoisomers
share a similar action on skeletal muscle sodium channels (this
study). It should be noted that the side effects of R(þ)-propranolol
may be similar to those of mexiletine, including CNS troubles or
cardiotoxicity in patients with heart disease, since these effectsmay
result from sodium channel blockade. Nevertheless, mexiletine use
is commonly associated with gastrointestinal disturbances, espe-
cially nausea (see for instanceDuff et al.,1983), that can signiﬁcantly
limit patient compliance or even fully exclude mexiletine therapy.
This latter effect may not be related to sodium channel blockade,
since it is not consistently observedwithother class I antiarrhythmic
drugs. Interestingly, nausea has been only reported in a very limited
number of patients receiving propranolol (Stephen, 1966). An other
limit of mexiletine therapymay be the lack of response in a number
of patients, which might stem from individual variations in drug
pharmacokinetics or mutation-induced sodium channel mutation/
polymorphism. In this case, other sodium channel blockers may be
useful. For instance, ﬂecainide has been shown to be efﬁcient in
a myotonic patient carrying the sodium channel V445M mutation
and resistant to mexiletine (Rosenfeld et al., 1997). Thus, R(þ)-
propranolol might be useful as an alternative to mexiletine in
a number of unsatisﬁed myotonic patients.
In conclusion, a recent systematic review has underscored the
lack of sufﬁcient randomized controlled trials of treatments for the
non-dystrophic myotonias (Trip et al., 2006). A controlled trial of
mexiletine versus placebo started in late 2008, and results are ex-
pected soon (clinicaltrials.gov). Such trials are difﬁcult to perform,
being hampered by the difﬁculty in quantifying myotonia and in
recruiting adequate number of patients to reach statistical power
(Matthews et al., 2010). In this context, a preclinical model appears
of great interest allowing a screening of compounds aimed at
individuating the most promising drug to be tested in humans. The
pharmacological model described in this study may encounter all
the requisites for such preclinical studies. Although mexiletine is
considered as a ﬁrst-line treatment in both sodium and chloride
channel myotonias, a number of patients cannot use this drug
because of contraindications, side effects, or lack of efﬁcacy. Among
the drugs tested in this study, the R(þ)-enantiomer of propranolol
may thus merit further investigation in humans with the aim of
increasing the arsenal of available antimyotonic drugs. Last but not
least, the ability of propranolol to reduce cell over-excitability
suggests a possible therapeutic value of this drug in various
conditions of neuron excitability disorders.
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